EXCLUSIVE ONLINE CONTENT
Alkahest, Inc. recently announced the initiation of a Phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first….
PharmaCyte Biotech recently announced it is about to embark upon a planned US FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC) at trial sites all over the US, and with that journey comes the….
Catalent, Inc. recently announced it has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of…..
Conatus Pharmaceuticals Inc. and Histogen Inc. recently announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly owned subsidiary of….
Albireo Pharma, Inc. recently announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once daily capsule in development for….